STAT3-Luc/EF1α-mCherry Reporter Cell Line - A549

STAT3-Luc/EF1α-mCherry Reporter Cell Line - A549 is a dual-reporter human lung adenocarcinoma cell line engineered to monitor STAT3 signaling activity and support cell normalization in the same experimental system. The parental A549 cell line is widely used in oncology, inflammation, and respiratory disease research because it retains key epithelial characteristics and responds to cytokine-mediated signaling. In this reporter model, a luciferase construct driven by STAT3-responsive elements produces a quantitative luminescent readout following activation of the JAK/STAT3 pathway. Constitutive mCherry expression under the EF1α promoter provides a stable fluorescent marker for cell tracking, transduction assessment, imaging, and normalization of cell number or viability-related variation. The combination of inducible luciferase activity and continuous red fluorescence enables sensitive, convenient, and reproducible analysis of pathway modulation in live cells.

This cell line is suitable for screening and characterizing compounds, biologics, antibodies, or genetic perturbations that regulate STAT3 activity. It can be used to evaluate pathway activation induced by cytokines such as IL-6, IL-11, oncostatin M, or other upstream stimuli, as well as inhibition by JAK inhibitors, STAT3-targeted agents, and anti-inflammatory candidates. Luciferase signals allow rapid quantitative measurement in multiwell formats, making the model particularly useful for medium- and high-throughput screening. The EF1α-mCherry marker facilitates fluorescence-based confirmation of cell density, morphology, and transfection or infection efficiency, while also supporting co-culture studies and live-cell imaging applications. In cancer research, the reporter line can help investigate STAT3-dependent mechanisms associated with proliferation, survival, epithelial–mesenchymal transition, immune evasion, drug resistance, and tumor microenvironment signaling. It is also applicable to target validation, CRISPR-based functional studies, and comparative profiling of STAT3 pathway responses under different treatment conditions.